本帖最后由 老马 于 2012-1-13 21:20 编辑 0 q6 d1 O- {: I- w6 Q/ d
6 _$ @0 Q; y8 n! }6 B6 l) Y爱必妥和阿瓦斯丁的比较
1 _/ I' I8 p7 t
; S8 A1 r- Z" \3 [' N% s: R
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
! x% `' Y, ?- }9 \
! j( M8 P0 A$ A+ F9 V
" u1 U! f% K; r9 Z- T+ ^5 _http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/6 m9 D/ M1 H& {+ |
==================================================. S0 S0 i% L* k) T" k: M( B
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)7 o; m6 b; g7 q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 p. q: C1 L; i3 x* fResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.( x' o9 U2 d9 L; Y# t% G, x; w: a
|